CliffBio
biologic

Besremi

ropeginterferon alfa-2b-njft

Loss of exclusivityNovember 2033projected — 12-year biologic exclusivity estimate
CompanyPharmaessentia Corporation →View the full company profile on CliffBio

Drug detail

Brand nameBesremi
Active ingredientropeginterferon alfa-2b-njft
Strength500MCG/ML
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalNovember 2021
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Besremi patent cliff — loss of exclusivity November 2033 | CliffBio